Most Read Articles
Elvira Manzano, 24 Mar 2021
The oral antiviral drug molnupiravir, given for 5 days, eliminated SARS-CoV-2 in the nasopharynx of patients with COVID-19, interim results of a phase IIa study have shown, boosting hopes for its potential use in the outpatient setting.
Audrey Abella, 09 Apr 2021
A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Roshini Claire Anthony, Yesterday

Skipping even one scheduled mammography screening prior to a breast cancer diagnosis could increase a woman’s risk of breast cancer mortality, according to a prospective, observational study from Sweden.

Galcanezumab: Empowering migraineurs on the journey to migraine-freedom

03 Mar 2021
Galcanezumab (Emgality®, DKSH Singapore) was developed to target calcitonin gene-related peptide (CGRP) to prevent migraine.1-3 At the symposium to mark the launch of Emgality® in Singapore on 23 January 2021 chaired by Dr Jonathan Ong, Dr Patricia Pozo-Rosich provided an overview of the current clinical and real-world evidence supporting the use of galcanezumab; a panel discussion led by Dr Ho King Hee and Dr Zhao Yi Jing also highlighted local headache specialists’ experience in the use of CGRP monoclonal antibodies (mAbs) in the treatment of patients with migraine.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Singapore digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 24 Mar 2021
The oral antiviral drug molnupiravir, given for 5 days, eliminated SARS-CoV-2 in the nasopharynx of patients with COVID-19, interim results of a phase IIa study have shown, boosting hopes for its potential use in the outpatient setting.
Audrey Abella, 09 Apr 2021
A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Roshini Claire Anthony, Yesterday

Skipping even one scheduled mammography screening prior to a breast cancer diagnosis could increase a woman’s risk of breast cancer mortality, according to a prospective, observational study from Sweden.